Riccardo Viola, Luca Mastorino, Matteo Megna, Giovanni Damiani, Paolo Gisondi, Giuseppe Argenziano, Ketty Peris, Francesca Prignano, Martina Burlando, Andrea Conti, Francesco Loconsole, Piergiorgio Malagoli, Iris Zalaudek, Sara Cacciapuoti, Francesco Bellinato, Anna Balato, Clara De Simone, Karin Chersi, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero
INTRODUCTION: Patients with psoriasis who have failed multiple biologic drugs have been defined as "multi-failure," although there are no clear data on the characteristics, comorbidities, and best treatment strategies for this population. Nowadays, given the next generation and the number of biologics available, patients are considered multi-failure when ≥4 biologics fail to achieve a good response. METHODS: Demographic characteristics and efficacy of anti-interleukin drugs in multi-failure patients were compared to a cohort of general psoriatic patients treated with IL-23 or IL-17 inhibitors...
January 5, 2024: International Journal of Dermatology